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Interleukin-I (IL-i) induces the formation ofPGE2 from monocytes, fibroblasts, muscle cells,
and brain tissue by increasing the intracellular concentrations of CA2+; this cation, in turn,
activates a phospholipase which cleaves arachidonic acid from either diacylglycerol or a
membrane phospholipid. Inaddition, IL-I increases thesynthesisofcyclooxygenase, as evidenced
by the increased conversion of arachidonic acid into prostaglandins after fibroblasts are
pre-incubated with IL-1. Evidence is also presented that fever is caused by interleukin-1- induced
prostaglandin E2-
INTRODUCTION
This paper will describe the effects of interleukin-1 (IL-1) on inducing prostaglan-
din E2 (PGE2). In addition, background information on the biochemistry and synthesis
ofprostaglandins will be presented.
BIOCHEMISTRY OF PGE2
Prostaglandins are synthesized from arachidonic acid (AA) a 20-carbon fatty acid
esterified to many cell phospholipids such as phosphotidylinositol [1]. AA iscleaved by
a phospholipase-an enzyme which can be activated by a variety ofstimuli such as Ca
[2] or hormones [3]. Once released, AA is oxygenated by cyclooxygenase to yield the
endoperoxide PGG2. This compound is then converted to PGH2 by the substitution of
H for OH on carbon number 15. PGH2 then acts as a substrate for various enzymes,
one of which, PGE2 isomerase, converts PGH2 into PGE2, an eicosonoid (i.e., a fatty
acid with 20 carbons) which has 1 trans and 1 cis double bond and a five-member ring
(carbon 8-12) containing an OH and a carbonyl group [1]. A second OH group is
joined to carbon number 15 on the side chain [2] (Fig. 1).
PGE2 synthesis can be blocked either by steroids (for example, glucocorticoids) or
non-steroidal anti-inflammatory drugs (NSAID; e.g., aspirin). Steroids decrease the
release of AA from phospholipids, perhaps by interfering with the activity of
phospholipase [4,5]. NSAIDs, on theother hand, inhibitcyclooxygenase byinterfering
with two sites on the enzyme, one of which is a lipophilic region which has a high
affinity for non-polar NSAIDs [1,6]. The ability of non-steroidals to inhibit PGE2
production may explain why these compounds are, under many circumstances, good
anti-pyretic agents [7].
EFFECTS OF IL-1 ON PGE2 PRODUCTION BY VARIOUS CELL TYPES
IL-1 induces many different cell types to produce PGE2; this phenomenon may
represent a general characteristic ofIL-1, although it must be stated that certain IL-I
mediated inflammatory effects (e.g., neutrophil degranulation) occur without PGE2
[8].
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Monocytes
When highly purified IL-1 is added to cell cultures of monocytes (1 x 106), PGE2
levels rise within one hour from essentially 0 pg/ml ofsupernatant fluid to around 140
pg/ml. This response can be blocked by the addition of the NSAID ibuprofen to the
incubation media [9]. The release of PGE2 by monocytes may be important in
immunoregulation, since PGE2 suppresses the proliferation ofcertain thymus-derived
lymphocytes (T cells) in response to antigens or mitogens [10]. Thus monocytic-
derived IL-1 which aids the blastogenesis of mitogen- or antigen-stimulated T cells
[11] also stimulates the release ofPGE2 from monocytes; thePGE2, in turn, then limits
T-cell proliferation (perhaps by altering intracellular levels ofcyclic nucleotides [12]),
a classic negative feedback system.
Muscles
During starvation, a decrease in plasma insulin levels permits the breakdown of
muscle proteins to occur. The released amino acids are converted by the liver into
glucose to meet the metabolic demands of the central nervous system [13,14]. In
addition, acetyl groups and ketones derived from the breakdown of adipose tissue
increase during starvation and act as the main source of fuel for the body (during
prolonged starvation, the brain switches fuel from glucose to ketones [13]). The use of
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ketones as a metabolic fuel allows the muscle tissues to be spared. On the other hand,
during infection insulin levels are not suppressed and ketone levels do not rise
[15,16,17]. As a result, metabolic demands, which may be higher than normal due to
the presence of fever, are met mainly by glucose derived from skeletal muscle amino
acids [18]. In addition, there is an increased utilization ofamino acids by the liver to
synthesize proteins associated with the inflammatory response-the so-called acute-
phase inflammatory protein [7,19]. Thus, prolonged infections can cause significant
muscle wasting, a common observation in patients with lymphomas and infectious
diseases such as tuberculosis [20].
Interleukin-1 appears to be at least one of the molecules involved in muscle
proteolysis during infections. Clowes et al. [21] haveshown thatthe proteolytic activity
of plasma from patients with trauma or sepsis is 190 percent of controls. The factor
responsible for this activity is a peptide with a molecular weight of 4 kd and has been
given the name proteolytic initiating factor (PIF). Baracos et al. in a series of
experiments demonstrated that highly purified IL-I increases the rate ofproteolysis of
rat muscle in vitro [22]. The proteolysis (measured by the rate of release of tyrosine
into the supernatant media) was accompanied by increased levels of PGE2; if
indomethacin or other NSAIDs were added to the media with IL-1, PGE2 release and
the rate of proteolysis both decreased to control levels. In addition, rate of proteolysis
and PGE2 production in the presence of IL-1 both increased at higher (i.e., 390 vs.
360C) incubation temperatures. Since IL-I breaks down in vivo into smaller molecular
weight molecules (i.e., 4 kd) which retain biologic activity [23], it is quite possible that
IL-I and PIF are at least parts ofthe same molecule. In fact, trypsin digestion of 15 kd
human IL-I produces a 4 kd product which has almost all ofthe proteolytic activity of
IL-1 and PIF [21,22,24]. Thus it appears that IL-1 is a catabolic molecule which
mediates proteolysis via PGE2.
Fibroblasts
The development of inflammatory lesions seen in rheumatoid arthritis may be due,
at least in part, to IL-1, since IL-1 has been identified in effusions from joints of
patients with rheumatoid arthritis [25,26]. In addition, monocyte-like cells from
synovial explants synthesize IL-1 in response to soluble products [27] released by
resident lymphocytes and to immune complexes [28]. Once released, IL-I induces the
synthesis of PGE2 [29] and collagenase from synovial stellate cells (i.e., fibroblast-like
cells found in rheumatoid arthritic lesions [30]). PGE2 leads to an increase in the
synthesis of osteoclast activating factor from lymphocytes [31], while collagenase
destroys the matrix of the joint capsule and generates chemotactic factors for
monocytes [32,33] and peripheral fibroblasts [34]. Moreover, degranulation products
of collagenase stimulate the release of IL-I from macrophages, resulting in a marked
increase in PGE2 and collagenase levels [35].
Additional experiments with human dermal fibroblasts have shown that IL-1
stimulates the release of PGE2 from these cells as well. The dermal fibroblasts start to
release PGE2 four to six hours after stimulation and continue to do so for at least 48
hours. Inhibitors of cyclooxygenase (i.e., ibuprofen) eliminate the production ofPGE2
by fibroblasts in response to IL-1; in addition, inhibitors of mRNA translation (e.g.,
anisomycin) decrease the stimulatory effects of IL-1, indicating that IL-1 induces
PGE2 production by first stimulating the synthesis of new protein [36].
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Neuronal Tissue
The ability of IL-I to initiate fevers appears to be a result of its effect on the CNS
rather than the periphery. More specifically, the action of IL-1 seems to be located
primarily in the pre-optic anterior hypothalamus (PO/AH) in that microinjections of
IL-1 into this area result in fever, while similar injections made into contiguous
hypothalamic tissue have little or no effect on body temperature [37,18)]. Further-
more, intravenous injection of IL-1 brings about a change in the discharge rate of
thermosensitive neurons; such responses have been consistent with mechanisms of
heat-conservation and production offever [39].
IL-1 appears to bring about a fever by first inducing the production of PGE2.
Briefly, PGE2 microinjected into the PO/AH produces fever in conscious animals
almost indistinguishable from that produced by intravenously injected IL-1 [40]. In
addition, endotoxin or IL-I injected intravenously leads to increased levels ofPGE2 in
the third ventricle or cisterna magna [41,42]. Hence a basic working hypothesis is that
IL-I induces PGE2 synthesis in certain cells (neuronal or non-neuronal-see below) of
the PO/AH. This concept is strengthened by the well-documented suppression ofIL-I
induced fevers by antipyretics that inhibit the synthesis ofPGE2 from arachidonic acid
[43]. Furthermore, PGE2 synthesis inhibitors have no effect on normal body tempera-
tures. It has been assumed that IL-I gains access to specific receptors in the PO/AH,
where new PGE2 is synthesized with the concomitant result offever. However, studies
using intrinsically injected '251I-labeled IL-1 have failed to show concentrations of the
pyrogen in the anterior hypothalamus [44]. Thus the receptive cells for IL-1 may lie
outside the blood-brain barrier (i.e., the organum vascularum lamina terminalis
[45]).
Brain minces stimulated in vitro with purified IL-1 release PGE2 within 30-60
minutes after stimulation [46]. Tissue from both the temporal cortex and anterior
hypothalamus release similar amounts of PGE2 in response to IL-1, indicating that
receptors for IL-1 are widespread. The NSAID ibuprofen, which reduces fever in
humans and is 20 times more potent than acetylsalicylic acid [47], markedly reduced
the amount ofPGE2 released by brain minces incubated with IL-1.
Ziel and Krupp, using brain homogenates, showed that IL-I increases the cerebral
prostaglandin synthetase system [48]. In addition, Fagan and Goldberg [49] have
shown that brain slices from rats which had been injected with endotoxin (an agent
which induces the release ofIL-I in vivo and in vitro) and which subsequently became
febrile released significantly more PGE2than brain slices fromsaline-injected animals.
In none ofthese experiments, however, are the cells which release PGE2 in response to
IL-I identified. However, Fontana et al. have demonstrated that cultured murine
astrocytes (macrophage-like cells which, however, are non-phagocytic and lack Fc and
C3receptors) release both IL-I and PGE2 in response to endotoxin [50]. Thus it may be
that astrocytes or other non-neuronal cells in the brain (i.e., dendritic cells) produce
PGE2 in response to IL-I during the pathogenesis offever (Table 1).
MODE OF ACTION OF IL-1 IN INDUCING SYNTHESIS OF PGE2
There is substantial evidence [51] that many agonists exert their effects by
influencing the metabolism ofphosphoinositides (compounds containing a molecule of
glycerol with two esterfied fatty acids and one molecule of inositol with one or more
phosphate groups). For example, vasopressin causes a rapid breakdown of phosphoti-
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TABLE 1
Tissues Known to Release PGE2
in Response to IL-I
1. Monocytes
2. Fibroblasts
3. Brain tissue and homogenates
4. Muscle strips
dylinositol 4,5 bisphosphate into diacylglycerol (DAG) and inositol triphosphate [52].
Inositol acts as a second messenger by increasing the levels ofintracellular Ca (coming
from either internal or external sources [53]), while DAG activates C-kinase, an
enzyme which phosphorylates specific regulating enzymes [54,55]. Most of the DAG
produced by receptor agonist interactions has arachidonic acid (AA) in its 2 position
[56]. Once DAG is formed, AA can be cleaved from the parent molecule by either
diacylglycerol lipase [57,58] or by a phosphatidic acid-specific phospholipase after
conversion of DAG into phosphatidic acid [59]. The AA, in turn, is converted into
prostaglandin by the cyclooxygenase enzyme pathway. The DAG enzymatic pathways
require increased intracellular levels of Ca"+ to operate. There is, however, an
alternate route by which AA can be generated. In this system a non-specific,
Ca-dependent phospholipase, which has a higherrequirement ofCa tooperatethan the
enzymes in the DAG pathway, cleaves AA from various cell membrane phospholipids
[60].
Since the enzymes responsible for the cleaving ofAA require Ca to be active, it may
be that IL-1 exerts its effects, in part, by causing an increase in intracellular levels of
Ca. Various experiments have shown that this is indeed thecase. Forexample, calcium
ionophores (e.g., A23187) can substitute for IL-1 in inducing PGE2 production and
proteolysis in rat muscle strips [61].
If Ca is removed from the media, A23187 induces significantly less PGE2 produc-
tion and muscle proteolysis. In addition, if mepacrine, an inhibitor of Ca-dependent
phospholipase, is added to the incubation media, PGE2 and proteolysis are both
decreased in response to A23187. This result indicates that Ca influx induces the
synthesis ofprostaglandin by first activating a phospholipase.
Besides activating Ca-dependent phospholipases, IL-I may also increase theactivity
ofcyclooxygenase. Human dermal fibroblasts when pre-incubated with IL-I converted
significantly more AA into prostaglandin when compared to control cells [62]. In
addition, microsomal cyclooxygenase activity increases after cells are pre-incubated
with IL-I for 48 hours. Ifthe fibroblasts are pre-incubated in the presence ofboth IL-I
and protein synthesis inhibitors, there is no increase in AAconversion. Thus, it appears
that IL-1 increases the activity of cyclooxygenase by increasing the enzyme's rate of
synthesis.
CONCLUSIONS
It seems likely that IL-1 causes fever by first inducing the synthesis of PGE2.
Evidence for this is that injection ofPGE2 into the brain produces a brisk monophasic
fever, as does IL-1. Moreover, intravenous injection of IL-1 leads to increases in
cerebrospinal fluid PGE2 which can be correlated with fever height. In addition,
NSAIDs eliminate or at least attenuate IL-1 induced fevers but not fevers caused by
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injection of PGE2. Finally, IL-1 stimulates the production of PGE2 from many cells
and tissues studied in vitro, including cells located in the brain.
IL-1 may initiate PGE2 synthesis by increasing internal concentration of Ca, a
cation which can activate a phospholipase(s) that cleaves AA from phospholipids or
DAG. In addition, IL-I increases the synthesis ofcyclooxygenase as evidenced by the
increased conversion of AA into PGE2 by fibroblasts preincubated with IL-1. This
increased conversion is blocked if the fibroblasts are incubated with both IL-1 and a
protein synthesis inhibitor, indicating that IL-1 induces the increased synthesis of
cyclooxygenase.
The exact role of PGE2 in fever awaits further experimental evidence. However,
with the recent availability of recombinant IL-1 [63], cells responsive to IL-1 in the
brain will be able to be identified, as well as their ability to synthesize PGE2 after IL-I
stimulation.
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